NCT01256359 2024-08-15
DOC-MEK
University of Oxford
Phase 2 Completed
Clinical Trials
8 trialsNCT02768766 2023-08-31
Intermittent Selumetinib for Uveal Melanoma
Columbia University
Phase 1 Completed
NCT02586987 2019-11-18
A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed
NCT01143402 2017-07-26
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
National Cancer Institute (NCI)
Phase 2 Completed
NCT00936221 2016-03-14
Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients
AstraZeneca
Phase 2 Completed
NCT00866177 2015-08-11
MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00338130 2014-08-13
Randomised Study to Compare the Efficacy of AZD6244 vs TMZ
AstraZeneca
Phase 2 Completed
NCT00710515 2014-08-13
Study to Assess the Effect of Dosing AZD6244 HydSulfate in the Presence and Absence of Food in Patients With Advanced Solid Malignancies
AstraZeneca
Phase 1 Completed